Business
Exopharm (ASX:EX1) share price plunges 17% after animal testing results
The Exopharm Ltd (ASX: EX1) share price is tumbling today after the company released its preclinical data from its osteoarthritis animal study, showing its two regenerative medical products had no effect on the rats studied.
At the time of writing, the Exopharm share price is down 15.7%, trading at 59 cents after hitting an intraday low of 55 cents.
Exopharm is a biopharmaceutical company focused on developing regenerative medicine. It’s currently investigating the therapeutic potential of two products, Plexaris and Cevaris, in treating osteoarthritis.
The company also aims to commercialise exosomes as therapeutic agents. Exosomes are membraneous structures that allow cells to communicate and have the potential to restore dying…
-
Noosa News24 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General22 hours agoSummah Richards, 12, mourned after fatal e-scooter in Laidley, Queensland
-
Noosa News24 hours agoMan arrested after police chase: Driver shot, woman dies in crash
-
General23 hours agoBoy’s drowning adds to ‘most horrific’ Easter toll